Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling

This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

360

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Dongguan, Guangdong, China
        • Dongguan People's Hospital
        • Contact:
      • Guangzhou, Guangdong, China
        • The First Affiliated Hospital of Guangzhou Medical University
        • Contact:
    • Henan
      • Zhengzhou, Henan, China
        • The First Affiliated Hospital of Henan University of Chinese Medicine
        • Contact:
    • Zhejiang
      • Ningbo, Zhejiang, China, 315000
        • The First Affiliated Hospital of Ningbo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria - Stable COPD cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70.
  2. Age 40 years or older, any sex.
  3. Clinically stable during the 4 weeks before enrollment, without a COPD exacerbation or initiation/change of systemic antibiotics or systemic glucocorticoids for worsening respiratory symptoms.
  4. Predominant TCM syndrome of lung qi deficiency, lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney qi-yin deficiency, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  5. Able to understand the study and provide written informed consent.
  6. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Stable COPD cohort:

  1. Systemic antibiotics or systemic glucocorticoids within 2 weeks before enrollment, or long-term systemic glucocorticoid maintenance therapy.
  2. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  3. Active pulmonary tuberculosis, pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  4. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  5. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  6. Allergy to study herbal components or a contraindication to herbal therapy.
  7. Pregnancy, breastfeeding, or planned pregnancy.
  8. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  9. Investigator judges participation unsuitable.

Inclusion Criteria - Hospitalized AECOPD cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70; current acute exacerbation assessed clinically.
  2. Age 40 years or older, any sex.
  3. Hospitalized for the current AECOPD episode, with screening and randomization completed within 24 hours after admission.
  4. Onset of acute worsening of respiratory symptoms no more than 5 days before enrollment.
  5. Cumulative systemic antibiotic and/or systemic glucocorticoid treatment for the current episode no more than 48 hours before enrollment.
  6. Predominant TCM syndrome of phlegm-heat obstructing the lung or phlegm-turbidity obstructing the lung, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  7. Able to understand the study and provide written informed consent.
  8. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Hospitalized AECOPD cohort:

  1. Deterioration not attributable to AECOPD; active pulmonary tuberculosis, invasive fungal disease, or pulmonary infection requiring pathogen-specific treatment as judged by the investigator.
  2. Pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  3. Systemic antibiotics or systemic glucocorticoids for reasons other than the current exacerbation within 2 weeks, or long-term systemic glucocorticoid maintenance therapy.
  4. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  5. Immediate need for intensive care, invasive mechanical ventilation, altered consciousness, or hemodynamic instability at enrollment.
  6. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  7. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  8. Allergy to study herbal components or a contraindication to herbal therapy.
  9. Pregnancy, breastfeeding, or planned pregnancy.
  10. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  11. Investigator judges participation unsuitable.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stable COPD - Lung Qi Deficiency - Optimized Yuping Yifei Formula

24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks.

Stable COPD, lung qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fangfeng 6 g, Wuweizi 6 g, Ziwan 9 g, and Sangbaipi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Active Comparator: Stable COPD - Lung Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Experimental: Stable COPD - Lung-Spleen Qi Deficiency - Optimized Liujun Fuzheng Formula

24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 12 g, Chenpi 9 g, ginger-processed Banxia 9 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Experimental: Stable COPD - Lung-Spleen Qi Deficiency - Innovative Qiyi Peitu Formula

24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 15 g, Shanyao 20 g, Yiyiren 20 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Active Comparator: Stable COPD - Lung-Spleen Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Experimental: Stable COPD - Lung-Kidney Qi Deficiency - Optimized Shenqi Naqi Formula

24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi deficiency: Dangshen 20 g, Huangqi 30 g, salt-processed Duzhong 12 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Fuling 12 g, and ginger-processed Banxia 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Experimental: Stable COPD - Lung-Kidney Qi Deficiency - Innovative Fufei Gushen Formula

24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi deficiency: Huangqi 30 g, Renshen 6 g, Yinyanghuo 9 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Gouqizi 15 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Active Comparator: Stable COPD - Lung-Kidney Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Experimental: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Optimized Shengmai Runyuan Formula

24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi-yin deficiency: Dangshen 15 g, Zhemaidong 10 g, Wuweizi 6 g, Shudihuang 15 g, Shanzhuyu 12 g, Shanyao 20 g, Huangqi 30 g, and Danshen 15 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Active Comparator: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Experimental: AECOPD - Phlegm-Heat Obstructing Lung - Optimized Qinbei Qingfei Formula

24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-heat obstructing the lung: Huangqin 9 g, Zhebeimu 10 g, Sangbaipi 12 g, Yuxingcao 20 g, Qingbanxia 9 g, Zisuzi 9 g, and honey-processed Mahuang 5 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Active Comparator: AECOPD - Phlegm-Heat Obstructing Lung - Standard Western Treatment

24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Experimental: AECOPD - Phlegm-Turbidity Obstructing Lung - Optimized Erchen Shunqi Formula

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Zisuzi 9 g, Baijiezi 6 g, and Laifuzi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Experimental: AECOPD - Phlegm-Turbidity Obstructing Lung - Innovative Banlou Kuanxiong Formula

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Gualoupi 9 g, Gualouren 6 g, Kuxingren 9 g, and Jiegeng 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Active Comparator: AECOPD - Phlegm-Turbidity Obstructing Lung - Standard Western Treatment

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in FEV1 Percent Predicted at Week 24 (Stable COPD)
Time Frame: Baseline (T0) and Week 24

Absolute change from baseline in post-bronchodilator forced expiratory volume in one second as a percentage of the predicted value (FEV1%pred).

Baseline (T0) and Week 24
Time to First Hospitalized COPD Exacerbation Through Week 24 (Stable COPD)
Time Frame: From baseline (T0) through Week 24

Time from T0 to the first acute COPD exacerbation requiring hospitalization. Exacerbations managed without hospitalization are not counted for this outcome.

From baseline (T0) through Week 24
Number of Hospitalized COPD Exacerbations Through Week 24 (Stable COPD)
Time Frame: From baseline (T0) through Week 24

Count of acute COPD exacerbations requiring hospitalization from T0 through Week 24. Episodes treated only in outpatient or emergency settings without admission are not counted.

From baseline (T0) through Week 24
Change in Dyspnea Numeric Rating Scale Score on Day 4 (AECOPD)
Time Frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

Absolute change from baseline in the average dyspnea numeric rating scale (NRS) score over the preceding 24 hours.

Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Proportion With at Least a 1-Point Improvement in Dyspnea NRS on Day 4 (AECOPD)
Time Frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

Proportion of participants whose average dyspnea NRS score over the preceding 24 hours decreases by at least 1 point from baseline.

Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Total Length of Hospital Stay for the Index AECOPD Admission
Time Frame: From hospital admission to discharge for the index AECOPD episode

Number of days from admission for the index acute exacerbation to hospital discharge.

From hospital admission to discharge for the index AECOPD episode

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in COPD Assessment Test (CAT) Score
Time Frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

Change from baseline in CAT total score in the stable COPD and AECOPD cohorts.

Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in TCM Syndrome Efficacy Score
Time Frame: Baseline and scheduled assessments through Week 24

Change from baseline in the syndrome-specific TCM symptom score using the appropriate stable-phase or AECOPD assessment scale.

Baseline and scheduled assessments through Week 24
Change in St. George's Respiratory Questionnaire (SGRQ) Score
Time Frame: Baseline, Week 12, and Week 24

Change from baseline in SGRQ total score.

Baseline, Week 12, and Week 24
Change in Modified Medical Research Council (mMRC) Dyspnea Grade
Time Frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

Change from baseline in the mMRC dyspnea grade, an ordinal measure of breathlessness, in stable COPD and hospitalized AECOPD participants.

Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in Airway Wall Area Percentage on HRCT
Time Frame: Baseline and Week 24

Absolute change from baseline in airway wall area percentage (WA%) derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in Emphysema Index on HRCT
Time Frame: Baseline and Week 24

Absolute change from baseline in emphysema index derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in Airway Wall Thickness on HRCT
Time Frame: Baseline and Week 24

Absolute change from baseline in airway wall thickness derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in C-Reactive Protein Concentration
Time Frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in peripheral-blood C-reactive protein concentration as an inflammation marker.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-6 Concentration
Time Frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in interleukin-6 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-8 Concentration
Time Frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in interleukin-8 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Tumor Necrosis Factor Alpha Concentration
Time Frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in tumor necrosis factor alpha concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in FEV1 Percent Predicted After AECOPD
Time Frame: Baseline when feasible, Weeks 12 and 24

Absolute change from baseline in post-bronchodilator FEV1 percent predicted among hospitalized AECOPD participants able to undergo safe and valid spirometry.

Baseline when feasible, Weeks 12 and 24
Incidence of Adverse Events
Time Frame: From baseline through Week 24

Number and proportion of participants experiencing at least one adverse event during treatment and follow-up, with event type, severity, and relationship to study herbal treatment recorded.

From baseline through Week 24
Incidence of Serious Adverse Events
Time Frame: From baseline through Week 24

Number and proportion of participants experiencing at least one serious adverse event during treatment and follow-up, with severity, management, outcome, and relationship to study herbal treatment recorded.

From baseline through Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2026

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

May 1, 2030

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data underlying the results reported in the main publication, including baseline characteristics, treatment allocation, and outcome data, will be available upon reasonable request. Direct personal identifiers will not be shared.

IPD Sharing Time Frame

Beginning after publication of the main study results, subject to applicable institutional and ethics requirements.

IPD Sharing Access Criteria

Qualified researchers may request access by submitting a research proposal to the study contact, together with ethics approval where applicable. Requests will be reviewed by the study team and relevant institutional or ethics bodies. Approved researchers will receive de-identified data under a data-use agreement. Re-identification and onward sharing are prohibited.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe